Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Porr, Valneva (22/01/2025)

26.01.2025

Porr: German rail technology company Vossloh AG said on Wednesday that it has awarded an order from Austrian construction group PORR as part of the British high-speed rail project High Speed 2 (HS2). Vossloh will supply rail fastening systems for the slab track on the line between London and Birmingham for the end customer HS2 Ltd. The order has a volume of over €30 million and covers the period from 2025 to 2027.
Österreichische Post: weekly performance: 0.34%

Valneva: Austrian/French Valneva today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the fourth quarter of 2025, with the objective to extend the product label to this age group.
Valneva: weekly performance: 9.65%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (22/01/2025)


Partners









latest 21st Austria

21st Austria weekly - Porr, Valneva (22/01/2025)


26.01.2025, 1143 Zeichen



Porr: German rail technology company Vossloh AG said on Wednesday that it has awarded an order from Austrian construction group PORR as part of the British high-speed rail project High Speed 2 (HS2). Vossloh will supply rail fastening systems for the slab track on the line between London and Birmingham for the end customer HS2 Ltd. The order has a volume of over €30 million and covers the period from 2025 to 2027.
Österreichische Post: weekly performance: 0.34%

Valneva: Austrian/French Valneva today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the fourth quarter of 2025, with the objective to extend the product label to this age group.
Valneva: weekly performance: 9.65%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (22/01/2025)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S25/01: Christian Drastil (Plan CD)




 

Bildnachweis

Aktien auf dem Radar:Frequentis, Agrana, Bajaj Mobility AG, EuroTeleSites AG, Amag, UBM, FACC, OMV, Verbund, Porr, Rosgix, EVN, AT&S, Rosenbauer, voestalpine, Wienerberger, Wolford, Wolftank-Adisa, BKS Bank Stamm, Oberbank AG Stamm, CPI Europe AG, Österreichische Post, Semperit, Telekom Austria, RHI Magnesita, DAX, Siemens, HeidelbergCement, MTU Aero Engines, Henkel, Fresenius Medical Care.


Random Partner

UBS
UBS bietet weltweit finanzielle Beratung und Lösungen für private, institutionelle und Firmenkunden als auch für private Kundinnen und Kunden in der Schweiz. UBS mit dem Hauptsitz in Zürich hat eine weltweite Präsenz in allen wichtigen Finanzmärkten.

>> Besuchen Sie 55 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten